Business Wire

Armis Launches Armis Centrix™, the AI-powered Cyber Exposure Management Platform

13.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Armis, the asset intelligence cybersecurity company, today announced the launch of Armis Centrix™, the AI-powered cyber exposure management platform. Armis Centrix™ is a seamless, frictionless, cloud-based platform that proactively secures all your assets, remediates vulnerabilities, blocks threats and protects your entire attack surface.

Armis Centrix™ enables organizations to discover, contextualize, enrich and profile every asset in their environment whilst also building a line of defense by leveraging Armis Centrix™ Asset Intelligence risk scores, policies, alerting and visualizations and most importantly: prioritize efforts against the exposures that matter to your business. Armis Centrix™ also integrates with existing enforcement and ticketing tools to establish end-to-end workflows and true risk lifecycle management and track risk reduction efforts to easily report on progress made. Armis Centrix™ takes proactive measures, detects threats & stops attacks to establish operational workflows and track risk reduction.

“In a perimeter-less world, where assets are digitally connected, traditional cybersecurity boundaries no longer exist. Legacy on-premise systems and point solutions are no longer fit for purpose leaving your attack surface and most critical assets open and exposed to cyber criminals and multiple bad actors,” said Nadir Izrael, CTO and Co-Founder, Armis. “The sheer scale and dynamic nature of the attack surface necessitates an entirely different, AI-driven approach, and that’s what Armis Centrix™ is - the AI that powers a suite of powerful tools for managing cyber risk exposure.”

Armis Centrix™ helps organizations see, protect and manage their entire attack surface, continuously safeguarding their mission-critical assets from cyber threats. Born in the cloud and fueled by AI, only Armis Centrix™ delivers a true modular approach to cyber exposure management covering the most critical cybersecurity needs for our clients across 4 solutions:

  • Asset management and security - Complete asset inventory of all asset types allowing any organization to see and secure the attack surface
  • OT/IOT security - See and secure OT/IOT networks and physical assets, ensure uptime and build an effective & comprehensive security strategy
  • Medical device security - Complete visibility and security for all medical devices, clinical assets and the entire healthcare ecosystem - with zero disruption to patient care
  • Vulnerability prioritization and remediation - Consolidate, prioritize and remediate all vulnerabilities; improve mean time to remediation (MTTR) with automatic remediation and ticketing workflows

“This is a revolutionary advancement that will change the way in which companies answer key questions regarding their cybersecurity posture,” said Dana Gilboa, Chief Product Officer, Armis. “Armis can help organizations mitigate their cyber asset risks and protect the entire attack surface by providing the needed intelligence to align security and business efforts. With this approach, we can ultimately provide organizations with the peace of mind they need, allowing them to see, protect and manage all their critical assets.”

Armis Centrix™ is industry-agnostic, allowing Manufacturing, Health and Medical, Information Technology, Energy and Utilities, Financial Services, Transportation, Telecommunications and Media, Public Sector and many more to benefit from its capabilities. Additionally, Armis collaborates with the world’s premier global technology vendors to ensure its customers can seamlessly integrate the Armis Centrix™ platform with existing IT and security stacks.

If you would like to know more about Armis Centrix™, the cyber exposure management platform, visit armis.com/centrix or contact us at info@armis.com.

About Armis

Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization's cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, secure, protect and manage all critical assets. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society safe and secure 24/7. Armis is a privately held company headquartered in California.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Smiths Detection Celebrates Sale of its 2,000 th HI-SCAN 6040 CTiX 3D X-ray Scanner12.3.2026 11:00:00 EET | Press release

Smiths Detection, a global leader in threat detection and screening solutions, today announces the sale of its 2,000th HI-SCAN 6040 CTiX, an industry-leading 3D X-ray scanner with high-resolution 3D computed tomography images and intelligent AI-driven automatic detection capabilities. The HI-SCAN 6040 CTiX is deployed across over 100 airports in Europe, Asia-Pacific, the Middle East and the Americas. Operational experience across these regions has demonstrated consistent benefits for airports and passengers alike. Fewer false alarms mean faster, more reliable screening, and as threat profiles change, the technology keeps pace, strengthening security resilience over time. Meanwhile, in eligible locations, passengers no longer need to remove laptops or liquids from their bags, a small change that has a real impact on congestion at security checkpoints. Matt Clark, VP Commercial at Smiths Detection, said: “The sale of our 2,000th HI-SCAN 6040 CTiX is a powerful endorsement of the trust ai

COOLMAX CloakFX™ Fiber Makes Official Global Debut at Performance Days Munich12.3.2026 10:00:00 EET | Press release

The LYCRA Company will officially launch COOLMAX CloakFX™ fiber globally at Performance Days Munich, Europe’s leading functional fabric fair, March 18–19. This innovation is designed to help garments appear drier by minimizing visible sweat marks while delivering moisture management and cooling comfort. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317950119/en/ COOLMAX CloakFX™ fiber, the latest innovation from The LYCRA Company, helps garments appear drier by minimizing visible sweat marks and delivering moisture-wicking, cooling performance. Photo credit: The LYCRA Company COOLMAX CloakFX™ fiber is for brands, mills, and garment makers creating performance-driven activewear, workwear, and everyday apparel. The technology diffuses light at the fiber level using optical “masking” that reduces the visual appearance of moisture, helping to make sweat marks less noticeable. Because the technology is built into the durable

Egon Zehnder and IMD Join Forces to Boost Board Performance and Leadership Growth12.3.2026 10:00:00 EET | Press release

Egon Zehnder, the world’s premier leadership advisory and executive search firm, and IMD, the leading business school in global executive education, today announced a strategic partnership to facilitate board directors’ personal growth and elevate board performance. The partnership combines IMD's academic rigor and deep connections to global boards with Egon Zehnder's unparalleled expertise in leadership and board effectiveness. Together, they will co-create tailored development experiences that blend research, real-world diagnostics, and practical guidance to support directors navigating today's complex business environment. IMD’s research clearly shows that good governance is a driver of both corporate success and national competitiveness. Egon Zehnder’s global work in supporting the personal development of board directors and chairs has shown that, in times of accelerating change, this has become a decisive factor for success. “This collaboration comes at a pivotal moment,” said Dav

EcoOnline Launches Mega Trends Report as 2025 Momentum Reflects the Shift from Compliance to Connected Risk12.3.2026 10:00:00 EET | Press release

EcoOnline, a leading global provider of safety and sustainability software, today announced its inaugural EcoOnline Mega Trends Report, based on 18 months of primary research with business leaders and frontline workers. Seven mega trends reshaping the risk landscape The findings show a market-wide sense of urgency and shift towards connected risk data and vendor consolidation, with organisations increasingly treating compliance as the baseline while prioritising improved operations visibility, faster decision-making, and a need to future-proof their businesses with real-time insights and operational readiness. The report outlines seven macro trends, from the chemical safety maturity gap and the rise of lone work and contractor reliance to the central role of training and frontline engagement, and the need for responsible, trusted AI in safety. 2025 momentum that mirrors the mega trends In 2025, EcoOnline saw these market shifts reflected in customer usage, adoption, and product expansi

Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 08:00:00 EET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye